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Abstract
Background: In 2012 the WHO formally recognised that infants and preschool children are at significant risk of
schistosomiasis and qualify for treatment with praziquantel (PZQ). Targeted surveys determining both the performance and
safety of this drug are now needed in endemic areas. We have formally assessed parasitological cure and putative side-
effects in a prospective cohort of Schistosoma mansoni-infected children (aged 5 months–7 years old) in lakeshore settings
of Uganda.
Methodology/Principal Findings: From a total of 369 children found to be egg-patent for intestinal schistosomiasis, 305
were followed-up three to four weeks after PZQ treatment and infection status re-assessed. Separately, a previously tested
side-effect questionnaire was employed before and 24 hours after PZQ treatment to assess incidence and amelioration of
symptoms in young children and their mothers. While the overall observed parasitological cure was 56.4%, a significant
difference was found between a sub-set of children who had a history of multiple PZQ treatments (between one and four in
an 18 month period), where cure rate was 41.7%, and those who had never received treatment (cure rate was 77?6%). PZQ
proved to be safe, with only mild reported side effects which cleared within a month after treatment. Prevalence of reported
symptoms was significantly lower in children than in mothers, and fewer side-effects were reported upon subsequent
rounds of PZQ treatment.
Conclusion/Significance: Our findings show that PZQ treatment of young children resulted in satisfactory cure rates, and
marked reduction in egg-output, with only mild and transient reported side-effects. However, the cure rate is clearly lower
in younger children and those with history of previous treatment. Cure rate, but not egg reduction rate, was also lower in
children with heavier pre-intervention infection intensity. With chemotherapy now recommended as a long-term strategy
for disease control in young children, research into optimising the periodicity of targeted treatment strategies is now crucial.
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Introduction
Schistosomiasis is one of the major neglected tropical diseases
(NTDs) affecting over 207 million people worldwide. Since the
agreement of the eight Millennium Goals in 2000, control of the
infection has gained much international interest and political
commitment, leading to the World Health Assembly 54.19
recommending regular de-worming of school-aged children at
risk of infection with anthelminthics [1].
Until very recently, preschool children (#5 years) were
considered at ‘‘low-risk’’ for infection based on the assumption
that children this young have little direct contact with schistosome
cercariae-infested water, and consequently they have consistently
been overlooked by mapping and treatment initiatives [2]. Recent
research studies conducted in Ghana, Mali, Niger, Nigeria, Sudan,
Uganda, Zanzibar and Zimbabwe, however, have clearly identi-
fied that this young age-class is living at risk for both urogential
and intestinal schistosomiasis, and preliminary results showed that
treatment with praziquantel (PZQ) is safe and efficacious [3–14].
For this reason, the World Health Organisation (WHO) is now
recommending that young children living in endemic areas should
be considered for treatment with PZQ during child health
campaigns at the standard dose of 40 mg/Kg [15]. Nonetheless,
there are still concerns associated with treatment of preschoolers
for schistosomiasis. Namely, infants are believed to be at risk of
choking, and there is a lack of prescribing information by the
pharmaceutical companies on toxicity, method of administration,
adverse effects and pharmacokinetics in this age group [16].
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This study therefore aimed to assess the performance and safety
of PZQ treatment in under seven year olds living in Schistosoma
mansoni endemic areas. Two different groups were investigated –
children who had never received PZQ treatment and children that
had been treated during a recent cohort study, in order to evaluate
the likely PZQ efficacy during a rolling programme of annual
treatment of preschool-aged children. In this way, we aim to build
on the present body of evidence and highlight issues that should be
addressed now as treatment of infants and preschoolers is scaled-
up [15].
Methods
Ethical statement, recruitment and treatment
The London School of Hygiene and Tropical Medicine,
London, UK (application no. LSHTM 5538.09) and the Ugandan
National Council of Science and Technology approved this study.
Before selection, all families received an information leaflet (in
local languages) detailing the objectives and procedures of this
study. Those who chose to participate had the study explained in
full by the local Vector Control Disease district officer. Before
enrolment, informed consent was given by mothers in writing or
by fingerprint (in cases of illiteracy). After collection of samples (at
both baseline and follow-ups) all children and guardians were
offered a standard 40 mg/Kg dose of PZQ (CIPLA, Mumbai,
India). In addition albendazole, or ALB (GSK, Uxbridge, UK),
was provided following WHO guidelines. All treatment was
supervised and confirmed by a nurse. For younger/smaller
children (,24 months old), PZQ tablets were crushed and mixed
with a spoonful of orange juice before administration. All children
were provided with additional juice and a food item (local bread)
at the time of treatment to ensure treatment was not taken on an
empty stomach and improve absorption of the drug.
Study site and design
These studies were conducted in seven different villages in rural
areas of Uganda where disease has been shown to occur, two on
the shores of Lake Albert, Buliisa District, and five on the shores of
Lake Victoria, Mayuge District. These seven villages have been
investigated as part of the Schistosomiasis in Mothers and Infants
(SIMI) project, looking at longitudinal dynamics of schistosomiasis,
malaria and associated morbidities in mothers and their preschool-
aged children (#6 year olds) [17–18].
Praziquantel efficacy study. The study involved a compar-
ison of PZQ efficacy in (i) a random sample of 507 children (mean
age 4.3, range, range 5 months–7 years old) from the SIMI cohort
who had been found to be egg positive at the closing stages of the
project or had received at least one PZQ dose in the past 18
months (‘‘previously treated’’), and (ii) a random sample of 472
children (mean age 3.7, range 5 months–7 years old) who had not
been previously treated (‘‘treatment-naı¨ve’’). In total, 369 were
found to be egg-patent for intestinal schistosomiasis. Of these, 305
were followed up 21–28 days later and infection status re-assessed
according to WHO guidelines. Of these 125 were ‘‘treatment-
naı¨ve’’ and 180 children were ‘‘previously treated’’. For more
details, see Fig. 1.
Praziquantel safety study. For analysis of the safety of
praziquantel treatment, data from the SIMI cohort studies were
used: a questionnaire was administered as part of the SIMI project
at baseline and follow-ups (6 and 12 month), immediately before
and 24 h after treatment, where mothers were asked to report
whether they or their children needed any medical assistance or
felt any of the following fourteen symptoms: dizziness, headache,
sleepiness, fatigue, vertigo, abdominal pain, cramps, nausea,
vomiting, diarrhoea, bloody stools, night fevers, sweating, lower
back pain and urticaria/rash. In total, side-effects data were
available from 781 children and 539 mothers at baseline, 171
children at six month follow-up and 167 children at twelve month
follow-up.
Inclusion and exclusion criteria
In order to be included in the treatment efficacy study, all
participants had to meet the following criteria: 1) aged below seven
years at recruitment; 2) had been resident in study area since birth;
3) had successfully swallowed the PZQ tablets prescribed and no
Figure 1. Number of volunteers upon enrolment and sample
submission compliance pre- and post-intervention surveys. No.
of children upon follow-up by age: 2 children aged 5–12 months, 23
children aged 13–24 months, 39 children aged 25–36 months, 45
children aged 37–48 months, 83 children aged 49–60 months, 66
children aged 61–72 months and 35 children aged 73–84 months
(missing age information for 12 children).
doi:10.1371/journal.pntd.0001864.g001
Author Summary
Although there is now extensive evidence for infection in
preschool-aged children, and even a change in WHO
guidelines endorsing treatment of this young age class in
endemic areas, very little work has been published on the
performance of praziquantel in children below the age of
six. Previous work on praziquantel performance in
preschool aged children focused on Schistosoma haema-
tobium infections (urogenital schistosomiasis), with few
observational studies published for S. mansoni infections
(intestinal schistosomiasis). With a formalised protocol, we
show that delivery of praziquantel to preschool-aged
children living in endemic areas is safe and efficacious.
However, this work has also shed light on dynamics never
previously explored. History of previous treatment and age
below three years proved to be determining factors for the
outcome of treatment. This work provides firm evidence
that in an endemic population certain young individuals
were simply not cured (no egg or antigen cessation) after
standard doses of praziquantel. This potential for non-cure
should not go overlooked since exposure to drug without
cure (either due to parasite or human factors) can lead to
emergence and spread of resistance to praziquantel.
Bearing in mind that praziquantel is the only commercially
available drug against schistosomiasis, we recommend
further research to understand these dynamics.
Treatment of Intestinal Schistosomiasis
PLOS Neglected Tropical Diseases | www.plosntds.org 2 October 2012 | Volume 6 | Issue 10 | e1864
rejection recorded; and 4) had provided two consecutive stool
samples and a single urine sample at baseline and follow-up.
Participants who had existing medical conditions or diarrhoea at
baseline were excluded from the study. In order to be included in
the safety study, all participants had to meet criteria 2 and 3 above,
and be aged 2–7 years at recruitment so that only children who
were able to verbally communicate with their mothers were
included to avoid reporting bias.
Parasitological diagnosis
Parasitological diagnosis of S. mansoni was performed using
double Kato-Katz thick smears prepared for two consecutive
day stool samples (41.7 mg of stool per smear) [19]. Micros-
copy was conducted by experienced Ministry of Health
technicians and supervised by a senior technician for quality
control. Results were expressed as eggs per gram of faeces (epg)
and infection intensities of S. mansoni were categorised as
follows: 1–99 epg as light, 100–399 epg as medium and
$400 epg as heavy infections according to WHO guidelines
[20]. A single urine sample from each provided a 50 ml aliquot
for testing of the presence of schistosome circulating cathodic
antigen (CCA) with a commercially available immuno-chro-
matographic dipstick (Rapid Medical Diagnostics, Pretoria,
RSA), a rapid diagnostic test for intestinal schistosomiasis. [21]
Trace results were considered positives.
Performance and safety of praziquantel treatment
The efficacy of PZQ (co-administered with ALB) for intestinal
schistosomiasis was evaluated qualitatively (cure rates) and
quantitatively based on a reduction in faecal egg counts (egg
reduction rates) within three to four weeks after treatment. Two
different cure rates (CR: the percentage of the infected population
negative for infection after drug treatment) were calculated, the
first using data from microscopy visualising egg-patent infections
and second using urine CCA-dipsticks [22]. The outcome of the
egg reduction rates (ERR) was calculated using two formulae
(ERR1 according to arithmetic mean and ERR2 according to
geometric mean) as described in Vercruysse and colleagues [23].
The CRs and the ERRs (1 & 2) were calculated for both sexes,
age-classes (A: 1 to 3 year olds, B: 4 to 7 year olds) and for the
different levels of pre-treatment egg excretion intensity.
A side-effect or incidence of symptom is defined as a symptom
absent before treatment and experienced after treatment. Ame-
lioration of a symptom is defined as a symptom that was
experienced before treatment and no longer present 24 hours
afterwards. To assess relative safety of PZQ (co-administered with
ALB) in children, the incidence and amelioration of symptoms in
children was compared to that in their mothers (all treated with
PZQ/ALB combination). To assess the continued safety of PZQ
(co-administered with ALB) throughout the project, the incidence
and amelioration of symptoms was compared between baseline
and follow-up surveys (among all treated children irrespective of
egg-patency). Additionally, the incidence and amelioration of
symptoms was compared between those treated with the
combination therapy (PZQ/ALB) and those treated with only
ALB (control group).
During the SIMI project, anti-malarials (Lonart, Bliss GVS
Pharma Ltd, India), and paracetamol were administered on-site to
children who tested positive for Plasmodium falciparum using
Paracheck-Pf (RDT, Orchid, India) and children who exhibited
symptoms of uncomplicated malaria. The administration of both
medications and prevalence of malaria were taken into consider-
ation during the analysis as potential confounders.
Statistical analysis
Data were collected using pro-forma data sheets in the field,
and then entered using EpiData (The EpiData Association,
Odense, Denmark) or Microsoft Excel. The data thus collated
were analysed using the R statistical package v 2?10?1 (The R
Foundation for Statistical Computing, Vienna, Austria) and
Microsoft Excel spreadsheet software. For percentage values,
95% confidence intervals (CI95) were estimated using the exact
method [24]. Prevalence comparisons were performed using
(one-tailed) Fisher’s exact modification of the 262 chi-squared
test [25]. For infection intensity values, the geometric mean of
Williams, GMW, was chosen as the measure of central
tendency due to the typical over-dispersion present in this
type of data [26].
Multivariate logistic regression was carried out to ascertain
factors (tested variables: age, sex, PZQ dosage administered,
history of previous treatment, daily water contact and pre-
treatment S. mansoni infection intensity) associated with ‘‘curing’’
after treatment. Furthermore, multivariate logistic regression was
used to identify factors [tested variables: age, sex, pre-treatment S.
mansoni (Kato-Katz) and malaria (Giemsa microscopy) prevalence
and co-administration of anti-malarial and antipyretic paraceta-
mol] associated with ‘‘incidence’’ and ‘‘amelioration’’ of symptoms
after treatment. Within village intra-correlation in the data was
accounted for using a generalized linear mixed model with
multivariate normal random effects (the random-effects of village
in our case), with penalized quasi-likelihood (function glmmPQL
in R) [27]. For each variable, odds ratio (OR) and P-values were
calculated, and a P-value ,0?05 was considered indicative of
statistical significance.
Results
Of the 1039 children recruited into the treatment efficacy study,
60 failed to provide replicate stool samples at baseline and a
further 64 children from the 369 already allocated children failed
to provide replicate stool samples upon follow-up; these children
were excluded from the study (See Fig. 1). A total 14 children
failed to provide urine samples at baseline; these children were
allocated into the study groups nonetheless if found positive and
only excluded during statistical analysis concerning the CCA rapid
diagnostic test.
The overall prevalence of egg-patent intestinal schistosomiasis
among the 979 children (5–93 months old, mean age 54 months
old) surveyed was 37?7% (GMw = 5?99 epg, max intensity
7284 epg), with the prevalence of high intensity infections
(.399 epg) reaching 8?9%. Prevalence of urine-CCA positive
individuals was significantly higher reaching 57?1% (P,0.0001).
For detailed information of infection intensity categories and
confidence intervals, see Table 1.
Praziquantel efficacy
Observed PZQ cure rate in the treatment-naı¨ve children
(N = 125) was 77?6%, ERR1 was 92?1% and ERR2 was 99?1%.
The maximum recorded intensity decreased from 7284 epg to
1524 epg, with the arithmetic mean decreasing from 394 epg to
31 epg and GMw decreasing from 108 epg to 1 epg. Observed
PZQ cure rate for the previously treated children (N = 180) was
41?7%, ERR1 was 72?8% and ERR2 was 92?2%. The maximum
recorded intensity decreased from 3906 epg to 3228 epg, with
arithmetic mean decreasing from 290 epg to 79 epg and GMw
decreasing from 102 epg to 8 epg. For detailed information on
cure rates according to age, sex and pre-intervention infection
intensity, as well as confidence intervals, see Table 2.
Treatment of Intestinal Schistosomiasis
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Observed PZQ efficacy based on CCA results in treatment-
naı¨ve children (N = 124) was 32?3% (CI95 24?1–41?2%). After
treatment, there was also a significant six-fold reduction in the
prevalence of strong (++/+++) CCA results, from 62?4% (CI95
53?2–70?9%) at baseline to 10.4% (CI95 5?7–17?2%) after
treatment. Observed PZQ efficacy in previously treated children
(N = 179) was 20?7% (CI95 14?9–27?4%). Similarly, after treat-
ment there was a significant reduction, albeit smaller (three-fold),
in the prevalence of strong CCA results, from 47?4% (CI95 40?0–
55?1%) at baseline to 15?6% (CI95 10?7–21?8%) after treatment.
According to multivariate logistic regression, becoming egg negative
after PZQ treatment was associated with age (1–3 year olds less likely to
cure than 4–7 year olds, OR = 3?53, P,0?001). Additionally, children
heavily infected with S. mansoni at baseline were less likely to cure after
treatment (OR = 0?47, P = 0?028). Finally, history of treatment also
influenced treatment outcome, with children who had been treated
once in the 18 months preceding this study being less likely to cure than
those naı¨ve for treatment (OR = 0?35, P = 0?003), and even lower odds
for those with history of two (OR = 0?06, P,0?0001) or more
(OR = 0.08, P,0?0001) treatments in the 18 months preceding this
study. In fact, the cure rate for children treated once (N = 93) in the
past was 60.0% (CI95 48?4–70?8%), for those treated twice (N = 65)
was 25?0% (CI95 14?0–38?9), and for those treated three times or more
(N = 61) was 29?2% (CI95 17?0–44?1%). This model controlled for sex,
dosage of PZQ received and daily time spent in water (proxy for
exposure), and neither were found to be significantly associated with
becoming egg-negative after treatment. For more details, see Table 3.
Safety of praziquantel
Side-effect data were available for 781 children and 539
mothers from SIMI’s baseline survey (raw data are available in
Supplementary Tables S1 and S2). Prevalence levels of egg-patent
S. mansoni infection in these study participants were 32?4% (CI95
29?1–35?8%) and 48?6% (CI95 44?3–52?9%), respectively for
children and mothers. Mothers reported a higher prevalence of
new symptoms post-treatment than their children for all listed
symptoms with the exception of bloody stools. On the other hand,
mothers reported a lower percentage of improvement of existing
symptoms after treatment than their children for all listed
symptoms with the exception of vomiting and bloody stools
(Fig. 2 A–B).
Prevalence of egg-patent S. mansoni infection in the children was
32?4% (CI95 29?1–35?8%), 34?6% (CI95 27?2–42?5%) and 32?5%
(CI95 25?4–40?3%), respectively for baseline, 6 month and 12
month follow-ups. As the cohort study progressed, the number of
cases of dizziness, sleepiness, fatigue, cramps, nausea, sweating and
night fevers post-treatment decreased significantly compared to
baseline. No symptom became more prevalent with time. As for
amelioration, with time children were more likely to clear
abdominal pain, bloody stools, sweating, night fevers and
urticaria/rash after treatment compared to baseline. Confidence
intervals and information on proportion of new and improving
symptoms are presented in Fig. 2C–D.
Side-effect data were available for 529 children treated with
PZQ and ALB combination therapy and 370 children treated with
ALB monotherapy only. Prevalence levels of egg-patent S. mansoni
infection in these study participants were 23?4% (CI95 19?7–
27?3%) and 6?6% (CI95 4?2–9?8%), respectively for combination
and monotherapy. Children who received PZQ were more likely
to report new cases of dizziness, abdominal pain, cramps, nausea
and diarrhoea, while children who received ALB monotherapy
were more likely to report night fevers. As for amelioration,
children who received PZQ were less likely to clear pre-existing
cases of abdominal pain and diarrhoea (Fig. 2E–F).
Table 1. Prevalence (in %) and arithmetic and geometric means (in epg) of S. mansoni infection as determined by microscopy and
rapid diagnostic test – Circulating Cathodic Antigen (CCA) - for all children (5 months–7 year olds) surveyed at baseline of the
treatment efficacy study.
Treatment-naı¨ve Previously treated Total
Kato-Katz CCA Kato-Katz CCA Kato-Katz CCA
No. surveyed 472 472 507 493 979 965
No. egg-patent 150 250 219 301 369 551
Prevalence (CI95):
Any positive 31.8 53.0 43.2 60.7 37.7 57.1
(27.6–36.2) (48.4–57.6) (38.8–47.6) (56.2–65.0) (34.6–40.8) (53.8–60.2)
1–39/trace 10.2 14.6 14.6 19.7 12.5 17.2
(7.6–13.3) (11.6–18.1) (11.6–18.0) (16.3–23.5) (10.5–14.7) (14.9–19.7)
40–99 epg/+ 5.3 15.7 8.7 16.2 7.1 16.0
(3.5–7.7) (12.5–19.3) (6.4–11.5) (13.1–19.8) (5.5–8.8) (13.7–18.4)
100–399 epg/++ 8.1 10.2 10.5 10.8 9.3 10.5
(5.8–10.9) (7.6–13.3) (7.9–13.5) (8.2–13.8) (7.5–11.3) (8.6–12.6)
$400 epg/+++ 8.3 12.5 9.5 14.4 8.8 13.5
(5.9–11.1) (9.7–15.8) (7.1–12.4) (11.4–17.8) (7.2–10.8) (11.4–15.8)
Arithmetic mean (CI95) 171.2 – 124.1 – 144.1 –
(111.0–231.5) (92.8–155.4) (112.8–175.3)
Geometric mean (CI95) 5.71 – 6.19 – 5.99 –
(2.47–6.95) (3.05–7.38) (2.85–7.12)
Prevalence of infection did not significantly differ between the two treatment groups (treatment-naı¨ve and previously treated) irrespective of diagnostic test employed.
doi:10.1371/journal.pntd.0001864.t001
Treatment of Intestinal Schistosomiasis
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According to multivariate logistic regression, presence of egg-
patent schistosomiasis in a child was associated with incidence of
dizziness (OR = 1?6, P = 0?049), headache (OR = 1?7, P = 0?077),
abdominal pain (OR = 2?1, P = 0?002), bloody stools (OR = 2?0,
P = 0?052) and night fevers (OR = 2?8, P,0?0001) after PZQ
treatment. Similarly, presence of heavy (.399 epg) S. mansoni
infection in a child was associated with incidence of abdominal
pain (OR = 3?6, P = 0?005), vomiting (OR = 4?7, P,0?001),
diarrhoea (OR = 3?7, P = 0?004), bloody stools (OR = 5?1,
P = 0?004) and night fevers (OR = 3?1, P = 0?044) after PZQ
treatment.
Discussion
Intestinal schistosomiasis in infants and preschool children from
the shoreline villages in our study areas is clearly a chronic public
health problem, where the need for PZQ treatment is especially
obvious. In these areas young children currently remain untreated,
and these untreated infections acquired in early childhood may
contribute to the worsening of their longer term clinical picture
[17]. In the case of intestinal schistosomiasis, hepato-splenomegaly
and periportal fibrosis regress very slowly post treatment, which
emphasises the necessity for prompt treatment before the intensity
of the infection becomes significant [28].
With children as young as one year of age affected by this
disease, recent WHO guidelines now endorse anti-schistosomal
treatment of preschool children [15]. However, some research
topics remain to be explored, such as pharmacokinetics of the
drug in young children, appropriate dosing and treatment
periodicity. Our findings provide clear evidence that PZQ
(40 mg/Kg) can confer benefit to the infants in terms of
significant cure rates and marked reduction in egg reduction
rates likely to avert development of chronic morbidity.
However, our results also show potentially important differ-
ences in relation to age, previous treatment and infection
intensity.
Table 2. Cure and egg reduction rates (CR and ERR, respectively) as determined by egg output, in % (and CI95), for treatment with
a single dose of praziquantel (40 mg/Kg) against intestinal schistosomiasis in very young children (5 months–7 year olds); (1) is ERR
of arithmetic mean, and (2) is ERR of geometric mean.
No. allocated No. followed-up CR ERR (1) ERR (2)
History of previous treatment
None 150 125 77.6 92.1 99.1
(69.3–84.6) (89.0–94.6) (94.9–100.0)
At least one treatment in the last 18 months 219 180 41.7 72.8 92.2
(34.4–49.3) (67.2–77.8) (85.1–96.6)
Single round in 18 months 93 80 60.0 75.6 96.5
(48.4–70.8) (70.0–80.6) (90.0–99.3)
Two rounds in 18 months 65 52 25.0 52.0 82.6
(14.0–38.9) (45.6–58.4) (73.4–89.7)
Three rounds or more in 18 months 61 48 29.2 84.8 91.0
(17.0–44.1) (80.8–88.3) (85.4–95.0)
Age class*
1–3 years 85 71 40.8 75.4 96.3
(29.3–53.1) (69.5–80.7) (89.4–99.2)
4–7 years 271 222 60.8 82.9 97.3
(54.1–67.3) (78.7–86.6) (92.3–99.4)
Sex*
Boy 164 135 60.0 88.3 97.1
(51.2–68.3) (84.5–91.6) (91.8–99.4)
Girl 200 167 53.9 76.8 95.2
(46.0–61.6) (71.9–81.2) (89.2–98.4)
Pre-intervention infection intensity
Low 191 155 61.3 34.2 89.3
(53.1–69.0) (19.6–51.3) (71.7–97.7)
Moderate 91 79 56.9 70.2 98.0
(45.3–68.1) (63.6–76.3) (95.0–99.5)
High 87 71 45.1 88.4 99.0
(33.2–57.3) (86.4–90.3) (98.0–99.5)
Total 369 305 56.4 82.2 96.2
(50.6–62.0) (77.7–86.2) (90.4–98.9)
*Information on sex and age of the child not available for all children.
doi:10.1371/journal.pntd.0001864.t002
Treatment of Intestinal Schistosomiasis
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While it is often assumed that the performance of PZQ is
relatively homogenous across the age classes, we have identified
factors influencing the outcome of treatment in very young children
which have not been previously highlighted in other age ranges.
Our results indicate that cure rate is lower in children under the age
of four, although ERR was less affected. Note that infection
intensities were significantly higher in 4–7 year olds comparing to 1–
3 year olds (GMw 111 epg v. 80 epg, respectively, P,0.0001). This
could also be related to different pharmacokinetics in infants, an
issue set to be explored in the initiative by the Merck Serono to
develop a PZQ paediatric formulation. Another possible explana-
tion for the lower cure rates in younger children could be lower anti-
worm immune responses, since chemotherapy in experimental
animals has been shown to be immune-dependent [29].
The lower cure rates in previously treated children (41.7% for
those receiving any prior treatment and 29.2% for those having
received three treatments) compared with treatment-naı¨ve chil-
dren (78%) was intriguing and requires explanation. This is not
explained by the child’s age or intensity of infection since the mean
and age ranges and infection intensity in the two groups were
essentially similar. These results suggest that there could have been
selection of parasites with lower sensitivity to PZQ as a result of
repetitive treatment, a phenomenon previously observed in other
settings [30–31]. Interestingly, results from the longitudinal cohort
project show that for certain individuals egg and urine-antigen
excretion never cease despite six rounds of treatment in a two-year
period (results not shown). While the possibility of putative
resistance to the drug is of concern, what should also be considered
is that these individuals could be immune-incompetent either due
to host-specific factors or due to co-infections.
In our study, CR results were significantly lower when using
urine-antigen detection as diagnostic tool, even though previous
work using an enzyme-linked immunosorbent assay (ELISA)-format
to detect CCA in sera samples has shown levels decreasing within
one week after treatment in adults [32]. Although lack of specificity
of the CCA could be an explanation for the disparity with the
parasitology we consider that relative lack of sensitivity of the Kato
Katz in detecting low intensity persisting infections a more likely
explanation [33–35]. Alternatively this novel commercially avail-
able test could also be indicating a cessation of egg production
despite parasites remaining active and metabolising in the host’s
vascular system after PZQ treatment. The issue of diagnostic
performance by either test used in this study requires further
evaluation. To this end, a larger data set is being analysed looking at
longitudinal dynamics (before and during mass treatment) of CCA
performance compared to Kato-Katz (manuscript in preparation).
Another factor to consider is that sensitivity to PZQ is
dependent on the maturity of the parasite, and in younger
children where a larger proportion of cases possibly result from
newly contracted infections, and especially if no second round of
treatment was given between baseline and follow-up [36], parasite
maturity could be contributing to reduction of observed drug
performance [37]. However, both groups of children included in
this study are from the same villages, meaning both groups have
an equal exposure potential to cercariae-infested waters. Addi-
tionally, daily water contact (as proxy for risky behaviour or
exposure) was taken into consideration when modelling the
outcome ‘‘cure’’, and was found to be statistically insignificant
(P-value = 0.24; see Table 3). Therefore the likelihood of recently
acquired infections at baseline or follow-up (i.e. presence of
immature parasites) should be biasing group results equally (lower
than expected PZQ efficacy), as opposed to explaining the marked
difference in treatment efficacy identified here.
In our setting, PZQ/ALB integrated therapy proved to be safe for
preschool children, with fewer reported side-effects than for their
mothers, who are currently targeted by mass drug administration
campaigns. In fact, the few side-effects reported at heightened levels
compared to children receiving ALB monotherapy were found to be
associated with the presence and intensity of infection, and all
cleared soon after, i.e. treatment of uninfected individuals leads to
Table 3. Multivariate logistic regression to ascertain variables associated with ‘‘cure’’ (i.e. to become egg-negative after treatment)
in 282 children (5 months–7 year olds).
Variable Baseline category Test category OR (CI95) P-value
Age 1–3 year olds 4–7 year olds 3.53 ,0.001
(1.75–7.12)
Sex Boy Girl 0.70 0.22
(0.40–1.23)
Dosage of praziquantel received at baseline 34.6 mg/Kg* +1 mg/Kg 0.96 0.49
(0.85–1.08)
No. treatment rounds in the past 18 months Never been treated One round 0.35 0.003
(0.17–0.71)
Two rounds 0.06 ,0.00001
(0.03–0.15)
Three or more rounds 0.08 ,0.00001
(0.04–0.20)
Daily time in water 0 hours +1 category 0.85 0.24
(0.65–1.11)
Was infection at baseline .399 epg (heavy)? No Yes 0.47 0.028
(0.24–0.92)
Time in water categories: 0 = zero hours, 1 =,30 min, 2 = 30–60 min, 3 = 60–120 min, 4 =.120 min.
*34.6 mg/Kg was the minimum dosage given in our survey population, while the maximum dosage was 45.1 mg/Kg.
doi:10.1371/journal.pntd.0001864.t003
Treatment of Intestinal Schistosomiasis
PLOS Neglected Tropical Diseases | www.plosntds.org 6 October 2012 | Volume 6 | Issue 10 | e1864
no adverse reactions. There are likely to be biases in parental
reporting of symptom on behalf of children, but this approach has
been used successfully in previous studies [5,7].
Our results clearly highlight a need for further research into
understanding the human factors influencing clearance of infection
post-treatment. While there are tools already available for inclusion of
younger children in mass treatment campaigns, such as an extended
version of the current WHO dose pole [38], this study brings to light
the potential problem of low cure rate (41.7%) in preschool children
with history of previous treatment. Our observation that preschoolers
receiving repetitive treatment in a period of 18 months are less likely to
clear infection than children naı¨ve to treatment indicates that treatment
of children this young should be conducted under different periodicity
than that for school-aged children. The potential for non-cure should
not go overlooked, since the emergence of resistance to the only
commercially available drug for schistosomiasis would undermine
ongoing African control programmes. Nevertheless, the recent change
in international policy, the availability of tools for pragmatic dosing of
Figure 2. Percentage of symptoms reported after treatment (left column) and percentage of symptoms ameliorated (right column).
A side-effect is defined as a symptom absent before treatment and experienced after treatment; amelioration of a symptom is defined as a symptom
that was experienced before treatment and no longer present 24 hours afterwards. A–B: children (N = 781) v. mothers (N = 539); C–D: baseline
(N = 781) v. follow-ups (children only, N = 171 and 167, respectively for 6 and 12 month follow-ups); E–F: PZQ+ALB integrated chemotherapy (N = 529)
v. ALB monotherapy (N = 370, children only).
doi:10.1371/journal.pntd.0001864.g002
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the young child and the results reported here on the performance,
albeit far from perfect, and safety of PZQ are encouraging premises for
improvement of global child health.
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